Cite
HARVARD Citation
Motzer, R. et al. (2023). Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 401 (10379), pp. 821-832. [Online].